In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
JAMA
|
March 26, 2026
FDA’s Promising New Framework for Rare Genetic Diseases
The ability to treat the underlying causes of rare genetic diseases is a new scientific achievement after many years when…
For more
Axios
|
March 26, 2026
Pinnacle Medicines raises $89M for oral peptide development
Pinnacle Medicines, developer of oral peptides for immunology and cardiometabolic diseases, raised an $89 million Series B. Oral peptide drugs…
For more
ABC (WJBF-TV)
|
March 23, 2026
Augusta Fire Dept. holds esophageal pre-cancer screenings for firefighters, staff
Firefighters face many dangers when battling a blaze, including an increased risk of certain cancers. That’s why the Augusta Fire…
For more
FOX 26
|
March 20, 2026
Experimental cell therapy keeps Houston father of 3 diagnosed with aggressive malignant tumor alive
Glioblastoma, the most common malignant brain tumor, is among the deadliest cancers, with most patients facing extremely short survival timelines….
For more
NPR
|
March 18, 2026
Regaining Function After Spinal Cord Injury: A New Path Forward? Dr. Adam Rogers, CEO, NervGen Pharma
On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s…
For more
The Scientist
|
February 7, 2026
From Discovery to Therapy: The Rise of Reprogrammed Tregs
Nobel Prize winner Shimon Sakaguchi, a pioneer in regulatory T cell (Treg) biology, discusses the path from early observations to…
For more
WGN-TV
|
February 5, 2026
New drug may help spinal cord injury patients regain function and hope
There is a new hope for people with spinal cord injuries. Doctors are using an experimental, easy to deliver drug,…
For more
The New York Times
|
January 9, 2026
Nothing Eased the Pain in His Chest. What Was Causing It?
Doctors ruled out a heart attack, but the patient had a sense that something was very wrong. The 52-year-old man…
For more
Investor’s Business Daily
|
January 8, 2026
Biotech Stocks’ Dark Winter Is Over. What That Means For Investors.
The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by…
For more
Fierce Pharma
|
January 6, 2026
3 biopharma CEOs explain why they are ‘authentically optimistic’ for 2026
While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would…
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
